Industrialization of AAV manufacturing by Xcite® transient and stable production platforms

Cell & Gene Therapy Insights 2025; 11(6), 697–713

DOI: 10.18609/cgti.2025.078

Published: 21 July
Innovator Insight
Suparna Sanyal, Peng Wang

Current challenges in AAV manufacturing include limited production efficiency, difficulties in scaling up processes, expensive materials, complex supply chains, and variability in results between batches. The key to overcoming these challenges is to industrialize AAV manufacturing by improving scalability and efficiency. Novel AAV transient transfection and stable producer cell line platforms have been designed to optimize AAV yields and packaging efficiency. The packaging efficiency for AAV is a crucial quality attribute for the manufacturing and industrialization of AAV production. By increasing the full/total capsid ratio of AAVs, it is possible to reduce dosage and subsequently cost of goods. In order to meet productivity and scalability goals, it is important to choose the appropriate manufacturing approach.